- Home
- ATNM vs ABVC Comparison
ATNM vs ABVC Comparison
Compare ATNM & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- ABVC
- Stock Information
- Founded
- ATNM 2000
- ABVC 2015
- Country
- ATNM United States
- ABVC United States
- Employees
- ATNM N/A
- ABVC N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- ATNM Health Care
- ABVC Health Care
- Exchange
- ATNM Nasdaq
- ABVC Nasdaq
- Market Cap
- ATNM 50.2M
- ABVC 52.1M
- IPO Year
- ATNM N/A
- ABVC N/A
- Fundamental
- Price
- ATNM $1.61
- ABVC $2.86
- Analyst Decision
- ATNM Strong Buy
- ABVC
- Analyst Count
- ATNM 2
- ABVC 0
- Target Price
- ATNM $4.50
- ABVC N/A
- AVG Volume (30 Days)
- ATNM 122.2K
- ABVC 82.7K
- Earning Date
- ATNM 11-13-2025
- ABVC 11-13-2025
- Dividend Yield
- ATNM N/A
- ABVC N/A
- EPS Growth
- ATNM N/A
- ABVC N/A
- EPS
- ATNM N/A
- ABVC N/A
- Revenue
- ATNM N/A
- ABVC $391,242.00
- Revenue This Year
- ATNM N/A
- ABVC $735.18
- Revenue Next Year
- ATNM N/A
- ABVC N/A
- P/E Ratio
- ATNM N/A
- ABVC N/A
- Revenue Growth
- ATNM N/A
- ABVC 186.84
- 52 Week Low
- ATNM $1.03
- ABVC $0.40
- 52 Week High
- ATNM $2.41
- ABVC $5.48
- Technical
- Relative Strength Index (RSI)
- ATNM 45.72
- ABVC 49.97
- Support Level
- ATNM $1.60
- ABVC $2.64
- Resistance Level
- ATNM $1.70
- ABVC $2.90
- Average True Range (ATR)
- ATNM 0.07
- ABVC 0.16
- MACD
- ATNM -0.01
- ABVC 0.01
- Stochastic Oscillator
- ATNM 32.14
- ABVC 55.64
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.